نتایج جستجو برای: hiv fusion inhibitors

تعداد نتایج: 504964  

Journal: :Vaccines 2021

Innate responses during acute HIV infection correlate with disease progression and pathogenesis. However, limited information is available about the events occurring first hours of in mucosal sites transmission. With an ex vivo HIV-1 challenge model human colorectal tissue we assessed induced by R5- X4-tropic isolates 24 h exposure. Microscopy studies demonstrated virus penetration up to 39 μm ...

2003
H K Thaker M H Snow

Altogether 42 million people worldwide have been infected with HIV, and 12 million have died over the last 20 years. Effective antiretroviral therapy has lead to sustained HIV viral suppression and immunological recovery in patients who have been infected with the virus. The incidence of AIDS has declined in the Western world with the introduction of effective antiretroviral therapy. Questions ...

2013
Leonardo Augusto Luvison Araújo Sabrina E. M. Almeida

Entry of HIV-1 into a host cell is a multi-step process, with the viral envelope gp120 and gp41 acting sequentially to mediate the viral attachment, CD4 binding, coreceptor binding, and fusion of the viral and host membranes. The emerging class of antiretroviral agents, collectively known as entry inhibitors, interfere in some of these steps. However, viral diversity has implications for possib...

Journal: :Postgraduate medical journal 2003
H K Thaker M H Snow

Altogether 42 million people worldwide have been infected with HIV, and 12 million have died over the last 20 years. Effective antiretroviral therapy has lead to sustained HIV viral suppression and immunological recovery in patients who have been infected with the virus. The incidence of AIDS has declined in the Western world with the introduction of effective antiretroviral therapy. Questions ...

2010
Michael A. Lobritz Annette N. Ratcliff Eric J. Arts

Entry inhibitors represent a new class of antiretroviral agents for the treatment of infection with HIV-1. While resistance to other HIV drug classes has been well described, resistance to this new class is still ill defined despite considerable clinical use. Several potential mechanisms have been proposed: tropism switching (utilization of CXCR4 instead of CCR5 for entry), increased affinity f...

Journal: :Current Biology 2000
Oliver T. Fackler B.Matija Peterlin

Enveloped viruses enter target cells by membrane fusion or endocytosis. In the latter case, fusion of the viral envelope is induced by the acidic pH of the endocytic vesicle [1]. As with most other retroviruses, entry of the human immunodeficiency virus (HIV) is thought to be exclusively by pH-independent membrane fusion after interaction of its envelope with CD4 and a chemokine co-receptor on ...

2013
Lijun Chao Lu Lu Hengwen Yang Yun Zhu Yuan Li Qian Wang Xiaowen Yu Shibo Jiang Ying-Hua Chen

The HIV-1 envelope glycoprotein (Env) gp41 plays a crucial role in the viral fusion process. The peptides derived from the C-terminal heptad repeat (CHR) of gp41 are potent HIV fusion inhibitors. However, the activity of these anti-HIV-1 peptides in vivo may be attenuated by their induction of anti-gp41 antibodies. Thus, it is essential to identify antiviral peptides or proteins with low, or no...

Journal: :Molecular pharmacology 2007
Changhua Ji Jun Zhang Marianna Dioszegi Sophie Chiu Eileen Rao Andre Derosier Nick Cammack Michael Brandt Surya Sankuratri

A panel of four CCR5 monoclonal antibodies (mAbs) recognizing different epitopes on CCR5 was examined in CCR5-mediated cell-cell fusion assay, alone or in combination with a variety of small molecule CCR5 antagonists. Although no antagonism was observed between any of the CCR5 inhibitors, surprisingly potent synergy was observed between CCR5 mAbs and antagonists, and the synergistic activity wa...

2015
Xiaojie Zhu Yun Zhu Sheng Ye Qian Wang Wei Xu Shan Su Zhiwu Sun Fei Yu Qi Liu Chao Wang Tianhong Zhang Zhenqing Zhang Xiaoyan Zhang Jianqing Xu Lanying Du Keliang Liu Lu Lu Rongguang Zhang Shibo Jiang

Enfuvirtide (T20), is the first HIV fusion inhibitor approved for treatment of HIV/AIDS patients who fail to respond to the current antiretroviral drugs. However, its clinical application is limited because of short half-life, drug resistance and cross-reactivity with the preexisting antibodies in HIV-infected patients. Using an artificial peptide strategy, we designed a peptide with non-native...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید